**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 47906**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

**Gut microbiota contributes to the distinction between two traditional Chinese medicine syndromes of ulcerative colitis**

Zhang YL *et al*. Gut microbiota and two TCM syndromes

Ya-Li Zhang, Li-Ting Cai, Jun-Yi Qi, Yun-Zheng Lin, Yan-Cheng Dai, Na Jiao, You-Lan Chen, Lie Zheng, Bei-Bei Wang, Li-Xin Zhu, Zhi-Peng Tang, Rui-Xin Zhu

**Ya-Li Zhang, Jun-Yi Qi, You-Lan Chen, Zhi-Peng Tang,** Institute of Digestive Diseases, LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

**Li-Ting Cai, Yun-Zheng Lin, Na Jiao, Bei-Bei Wang, Rui-Xin Zhu,** Department of Bioinformatics, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China

**Yan-Cheng Dai,** Department of Gastroenterology, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China

**Lie Zheng,** Department of Gastroenterology, Traditional Chinese Medicine Hospital of Shanxi Province, Xi’an 710000, Shanxi Province, China

**Li-Xin Zhu,** Genome, Environment and Microbiome Community of Excellence, the State University of New York at Buffalo, Buffalo, NY 14214, United States

**ORCID number:** Ya-Li Zhang (0000-0002-3538-9832); Li-Ting Cai (0000-0001-6173-7143); Jun-Yi Qi (0000-0001-8294-9268); Yun-Zheng Lin (0000-0002-0378-503X); Yan-Cheng Dai (0000-0001-9919-4033); Na Jiao (0000-0003-3976-6313); You-Lan Chen (0000-0002-4304-5693); Lie Zheng (0000-0002-8243-3736); Bei-Bei Wang (0000-0002-8864-5174); Li-Xin Zhu (0000-0001-7904-1769); Rui-Xin Zhu (0000-0002-5070-6453); Zhi-Peng Tang (0000-0001-5695-8072).

**Author contributions:** Zhang YL and Cai LT contributed equally to this work, and both performed the majority of research; Qi JY, Lin YZ, Dai YC, Jiao N, Chen YL, Zheng L, and Wang BB performed the research and analyzed the data; Zhu LX, Zhu RX, and Tang ZP designed and coordinated the research; Zhang YL and Cai LT wrote and revised the paper.

**Supported by** the National Natural Science Foundation of China, No. 81704009, No. 81873253, No. 81573892, and No. 81770571; and the Project of Shanghai Municipal Health and Family Planning Commission, No. 201640122.

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

**Informed consent statement:** All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.

**Conflict-of-interest statement:** The authors declare that there are no conflicts of interest related to this study

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Zhi-Peng Tang, PhD, Doctor, Professor,** Institute of Digestive Diseases, LongHua Hospital, Shanghai University of Traditional Chinese Medicine,725 Wanping Road**,** Shanghai 200032, China.zhipengtang@sohu.com

**Telephone:** +86-21-6438-5700

**Received:** April 12, 2019

**Peer-review started:** April 15, 2019

**First decision:** May 16, 2019

**Revised:** June 2, 2019

**Accepted:** June 8, 2019

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

Ulcerative colitis (UC) is considered to be closely associated with alteration of intestinal microorganisms. According to the traditional Chinese medicine (TCM) theory, UC can be divided into two disease syndromes called Pi-Xu-Shi-Yun (PXSY) and Da-Chang-Shi-Re (DCSR). The relationships among gut microbiota, TCM syndromes, and UC pathogenesis have not been well investigated.

***AIM***

To investigate the role of gut microbiota in UC and the distinction of microbiota dysbiosis between PXSY and DCSR syndromes.

***METHODS***

From May 2015 to February 2016, UC patients presenting to LongHua Hospital who met the established inclusion and exclusion criteria were enrolled in this retrospective study. Fresh stool specimens of UC patients with PXSY or DCSR were collected. The feces of the control group came from the health examination population of Longhua Hospital. The composition of gut bacterial communities in stool samples was determined by the pyrosequencing of 16S ribosomal RNA. The high-throughput sequencing reads were processed with QIIME, and biological functions were predicted using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States.

***RESULTS***

The composition of gut bacterial communities in 93 stool samples (30 healthy controls, 32 patients with PXSY syndrome, and 31 patients with DCSR syndrome) was determined by the pyrosequencing of 16S ribosomal RNA. Beta diversity showed that the composition of the microbiota was different among the three groups. At the family level, Porphyromonadaceae, Rikeneliaceae, and Lachnospiraceae significantly decreased while Enterococcus, Streptococcus, and other potential pathogens significantly increased in UC patients compared to healthy subjects. At the genus level, *Parabacteroides*, *Dorea*, and *Ruminococcus* decreased while *Faecalibacterium* showed increased abundance in UC compared to healthy controls. Five differential taxa were identified between PXSY and DCSR syndromes. At the genus level, a significantly increased abundance of *Streptococcus* was observed in DCSR patients, while *Lachnoclostridium* increased in PXSY patients. The differential functional pathways of the gut microbiome between the PXSY and DCSR groups mainly included lipid metabolism, immunity, and the metabolism of polypeptides.

***CONCLUSION***

Our study suggests that the gut microbiota contributes to the distinction between the two TCM syndromes of UC.

**Key words:** Ulcerative colitis; Intestinal microbiota; Pi-Xu-Shi-Yun syndrome; Da-Chang-Shi-Re syndrome; Traditional Chinese medicine

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Ulcerative colitis (UC) is considered to be closely associated with alteration of intestinal microorganisms. According to the traditional Chinese medicine (TCM) theory, UC can be divided into Pi-Xu-Shi-Yun syndrome (syndrome of spleen deficiency and dampness, PXSY) and Da-Chang-Shi-Re syndrome (syndrome of dampness-heat in the large intestine, DCSR). This study showed that the gut microbiota was different between patients with PXSY syndrome and those with DCSR syndrome. The genus *Streptococcus* was significantly more abundant in DCSR patients than in PXSY patients, while *Lachnoclostridium* increased in PXSY patients. Our study suggests that the gut microbiota contributes to the distinction between the two TCM syndromes of UC.

Zhang YL, Cai LT, Qi JY, Lin YZ, Dai YC, Jiao N, Chen YL, Zheng L, Wang BB, Zhu LX, Zhu RX, Tang ZP. Gut microbiota contributes to the distinction between two traditional Chinese medicine syndromes of ulcerative colitis. *World J Gastroenterol* 2019; In press

**INTRODUCTION**

Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD). According to relevant epidemiological studies, the incidence of UC is high in Western developed countries, particularly in North America (19.2 per 100000 person-years) and Europe (24.3 per 100000 person-years)[1]. The incidence of UC has been increasing in Asia, especially in China, in recent years[2-4]. The high incidence of UC in China is particularly concentrated in coastal areas, such as Guangzhou (2.22 per 100000 person-years) and Hong Kong (1.66 per 100000 person-years)[5,6]. Notably, UC patients have a higher incidence of colorectal cancer than healthy individuals[7,8]. Moreover, UC is often difficult to treat and is accompanied by a high recurrence rate. Since different individuals have different manifestations of UC, more accurate diagnosis and treatment of UC for every patient have been emphasised, and precision medicine for UC is needed.

According to the traditional Chinese medicine (TCM) theory, the same disease can be divided into different syndromes, and different treatments would be used clinically depending on the different syndromes. For instance, UC can be divided into Pi-Xu-Shi-Yun syndrome (syndrome of spleen deficiency and dampness, PXSY) and Da-Chang-Shi-Re syndrome (syndrome of dampness-heat in the large intestine, DCSR)[9]. Shi-Re syndrome is caused by dysfunction of the Pi (“spleen”) and Wei (“stomach”), and Pi-Xu syndrome has been shown to be involved in dysfunction of the vegetative nervous system of the gastrointestinal tract and immune pathways[10]. PXSY syndrome is a deficiency syndrome, while the DCSR syndrome is a sthenia syndrome. Studies have proven that TCM works for treating UC patients[11-13] and that TCM drugs are closely associated with immunity[14,15], such as reducing pro-inflammatory cytokines[16]. Nevertheless, the essential molecular mechanisms of TCM remain unknown.

Although the pathogenesis of UC is not yet clear, most studies discuss that the dysbiosis of commensal bacterial populations is a major factor in disease pathogenesis, which interacts with genetic susceptibility and could lead to dysregulation of the immune response to bacterial antigens in IBD[17,18]. Round *et al*[19] suggested that dysregulation of the gut microbiota might be the cause of UC. The microbiota in the gut affects the health of the host by interacting with genes and the environment. Some studies[20-22] found that the biodiversity of intestinal bacteria in patients with UC is significantly reduced and that the increase in destructive microbiota in the gut leads to disorders in the intestinal environment. Guo *et al*[23] showed that the Chinese medicine “Red Ginseng” was effective in relieving symptoms of UC and could promote the growth of probiotic bacteria *in vitro*. However, the relationships among gut microbiota, TCM syndromes, and UC pathogenesis are unclear.

Because the majority of studies have focused on the relationship between intestinal microbiota and the onset of UC and the contribution of gut microbiota in these two distinct TCM syndromes is still unclarified, this study compared the difference in microbial composition and function between PXSY and DCSR syndromes to determine the molecular mechanism of TCM in UC by investigation of the gut microbiota.

**MATERIALS AND METHODS**

***Patient recruitment***

This study was approved by the LongHua Hospital, Shanghai University of Traditional Chinese Medicine. Three groups of adults were recruited in this study (PXSY patients, DCSR patients, and healthy controls). Volunteers under investigation in the hospital were approached if the doctors deemed that they had either UC or a normal colon at colonoscopy. Two types of TCM syndromes of UC, DCSR syndrome and PXSY syndrome, were identified according to the "dysentery" diagnosis standard of UC.

The main clinical manifestations of UC are diarrhoea, mucous pus, and blood accompanied by abdominal pain, tenesmus and back weight, and systemic symptoms of varying degrees. The course of disease is more than 4-6 wk. Mucous purulent blood is the most common symptom of UC. Currently, there is still a lack of the gold standard for UC diagnosis, which is mainly based on the combination of clinical manifestations and endoscopic, pathological, and histological findings as well as the exclusion of infectious and non-infectious colitis. We can distinguish these two syndromes according to patients' clinical manifestations, tongue coating, and pulse condition. Clinical manifestations of DCSR syndrome were abdominal pain, tenesmus, stools containing blood and white mucus, a burning sensation around the anus, and scanty, dark-yellow urine. The tongue coating was greasy and slightly yellow. Pulse was slippery and rapid. While clinical manifestations of PXSY syndrome were recurrent loose stools and increased frequency of bowel movements, especially after eating greasy food, poor appetite, gastric or abdominal distension, a sallow complexion, and lassitude. The tongue coating was pale and thin. The pulse was weak and thready[24,25].

The exclusion criteria for UC patients were: (1) below the age of 18 or above the age of 60 years; (2) use of microecological preparations or antibiotics within the previous two weeks; (3) previous gastrointestinal surgery; (4) severe hypertension, diabetes, coronary heart disease, or other internal diseases; (5) pregnancy, lactation, or planned pregnancy; (6) uncooperativeness; and (7) other autoimmune diseases.

***DNA extraction and PCR amplification***

Faecal samples were collected from volunteers and stored at -80 °C before DNA isolation. After the DNA was extracted, the integrity of the sampled bacterial genome was examined using agar gel electrophoresis. The V4 hyper-variable region was PCR-amplified with forward primer 515F (5’-GTGCCAGCCMGCCGCGG-3’) and reverse primer 806R (5’-GGACTACHVGGGTWTCTAAT-3’). Unique barcodes were attached to the primers to allow multiplex deep sequencing. The 25-μL reaction system contained 2 µL DNA extract, 0.4 µL forward primer, 0.4 µL reverse primer, 0.2 µL Taq DNA, and 2.5 µL 10 × buffer. PCR cycling parameters were initial denaturation at 95 °C for 5 min; 35 cycles of denaturation at 95 °C for 30 s, annealing at 60 °C for 30 s, and extension at 72 °C for 1 min; and a final extension at 72 °C for 10 min. The PCR product was electrophoresed on a 2.0% agarose gel for 30 min at 120 V, followed by staining with ethidium bromide (0.5 µg/mL) for 20 min, and the brightness of the image strip was observed.

***Processing sequencing samples***

Trimmomatic[26] (version 0.36) and QIIME[27] software (version 1.8.1) were applied for sequence processing and analysis. In this study, reads with a length less than 200 bp were excluded from further processing and analysis. All the joined sequences were identified as chimaeras with USEARCH[28], and chimaeric sequences were also filtered. Operational taxonomic units (OTUs) were grouped by a *de novo* strategy against the Greengenes database with an identity > 97%. Microbiota taxonomy was assigned by RDP classifier. In each group, OTUs with reads of more than half the sample size of that group were kept. Good’s coverage index was used to detect the sequencing depth. The Chao1 index was calculated to evaluate the microbial diversity. Principal coordinate analysis (PCoA) was performed to determine the degree of dissimilarity among groups using the unweighted UniFrac method.

***Prediction and differential analysis of functions***

The microbial 16S rRNA sequencing data were used to make OTU tables *via* the closed reference OTU picking method. The microbial community metagenome prediction was done with Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt)[29]. OTU tables were normalized by 16S rRNA copy number, followed by metagenome predictions against Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthology and compilation into KEGG pathways. Finally, linear discriminant analysis effect size (LEfSe)[30] on galaxy online (http://huttenhower.sph.harvard.edu/ galaxy)[31] was carried out to detect inner function differentials among groups. Linear discriminant analysis scores larger than 2 and *P*-values from the Kruskal-Wallis test less than 0.05 were considered significant.

***Statistical methods***

Since the distribution of each clinical characteristic followed a normal distribution except of age, the *P*-value of each clinical characteristic was calculated by the chi-square test, while age was estimated by the rank sum test. A Kruskal-Wallis test with post hoc Dunn’s test was performed to compare relative abundances of taxa and microbial diversity among the three groups. To examine significant differences between the UC and control groups, a Wilcoxon rank-sum test with two-tailed distribution was performed. Differential taxa were identified with adjusted *P-*values < 0.05 (adjusted by the Bonferroni correction) for multiple comparisons, and a false discovery rate < 0.05 was considered significantly different.

**RESULTS**

***Human subjects***

Clinical characteristics of the 93 human subjects are shown in Table 1. Of these subjects, 63 were diagnosed with UC based on colonoscopy at LongHua Hospital, Shanghai University of Traditional Chinese Medicine. Among these volunteers, 31 UC patients were diagnosed with DCSR syndrome, 32 UC patients were diagnosed with PXSY syndrome, and 30 individuals had no specific digestive system diseases and were recruited as healthy controls. All volunteers provided informed consent before participating in the experiment. Among all the individuals, there was no significant difference in any clinical factor, such as gender, age, or inflammation location (*P* > 0.05) (Table 1). PCoA plots in Appendix Figure 1 suggests that gender and age had no obvious influence on sample clustering.

***Characterization of microbiota ecological diversities***

Gut microbiomes of 93 samples (Table 1) were analysed by 16S rRNA pyrosequencing, and a total of 3494198 sequences were obtained after quality control. Good’s coverage estimator was determined to measure the sequencing depth of each sample. The alpha rarefaction curve (Figure 1) of each sample reached at the platform extracted approximately 2700 sequences per sample, and Good’s coverage estimator of each group approached 100% (>98.9%), indicating that the sequencing depth was sufficient to reflect the majority of bacterial sequences in all samples.

The beta diversities of the healthy control, PXSY syndrome, and DCSR syndrome cohorts were assessed by UniFrac analysis. The PCoA plot (Figure 2) showed that the majority of samples were clustered by health status but not by age or gender (Appendix Figure 1), reflecting that an association between health status and gut microbiomes existed. Moreover, the UC patients were clustered into two groups according to the two TMC syndromes, PXSY and DCSR, which indicated that the gut microbiota may contribute to distinguishing these two syndromes.

***Differences in microbiomes between healthy controls and patients with UC***

Non-parametric statistical testing methods were used to analyse the differential microbes between UC patients and healthy subjects. The microbes with an average abundance greater than 1% in any of the groups (Table 2) are as follows:

At the family level, the relative abundance of Paraprevotellaceae, Porphyromonadaceae, Rikenellaceae, and Lachnospiraceae decreased in UC patients compared to healthy individuals, while Enterococcaceae and Streptococcaceae were significantly abundant in UC patients. At the genus level, the abundance of *Parabacteroides*, *Alistipes*, *Ruminococcus*, *Phascolarctobacterium*, *Dorea*, *Sutterella*, and an uncultured genus belonging to the family Lachnospiraceae decreased in the UC group compared to healthy controls. On the other hand, the genera *Enterococcus*, *Streptococcus,* and *Faecalibacterium* were more significantly abundant in UC patients than in the healthy cohort. Notably, the families Porphyromonadaceae and Lachnospiraceae exhibited a similar depleted trend in UC patients, as some studies have previously reported[32-34]. It has also been reported that the genera *Enterococcus* and *Streptococcus* were differentially abundant in UC, while *Ruminococcus* was also significant in the healthy cohort[24,35].

***Differential microbiome analysis of the two UC syndromes***

Intestinal microbiomes that were significantly different between PXSY and DCSR as determined by the Kruskal-Wallis test are highlighted in Table 2. Bacteroides and Firmicutes were the dominant phyla in these samples, and differed significantly between the PXSY and DCSR groups. Firmicutes was significantly abundant in the DCSR cohort, while Bacteroides was differentially abundant in the PXSY cohort. The differential taxa at the family and genus levels are shown in Figure 3. Within the phylum Firmicutes, the family Streptococcaceae was significantly different between DCSR syndrome and PXSY syndrome patients. At the genus level, *Streptococcus* and *Lachnoclostridium* were significantly different between DCSR and PXSY patients. Known as a lactate producer, Streptococcus was more abundant in DCSR patients than in PXSY patients and healthy controls, indicating that DCSR patients might have more lactate in the gut than PXSY patients and controls. *Lachnoclostridium* is more abundant in PXSY patients than in DCSR patients and healthy controls. The species *Clostridium citroniae*, which belongs to the genus *Lachnoclostridium*, also exhibited the same tendency.

***Lactate producers are abundant in DCSR syndrome patients***

The lactate producer Streptococcus was increased in the DCSR group, which led us to explore the lactate-producing taxa in PXSY and DCSR syndromes. The relative abundance of the main lactate producers in the gut is shown in Figure 4. All of the main lactate producers showed a trend of increased relative abundance. Compared to healthy controls and PXSY patients, DCSR syndrome patients had significantly abundant lactic acid bacteria, suggesting that more lactic acid might accumulate in the guts of DCSR patients than in the guts of PXSY patients.

***Differential functions between PXSY and DCSR***

The gut microbiome composition of all groups was determined based on 16S rRNA gene sequencing data. KEGG pathways were categorized using PICRUSt, and ten differential functions were identified with LEfSe. The functional pathways of gut microbiomes between the PXSY and DCSR groups are shown in Figure 5. After differential function analysis, the functions related to liquid metabolism, such as synthesis and degradation of ketone bodies and fatty acid metabolism, were more significant in DCSR patients. Moreover, the RIG-I-like receptor (RLR) signalling pathway and benzoate degradation were also more abundant in DCSR patients. In the PXSY cohort, the genetic information processing functions of protein processing in the endoplasmic reticulum and the carbohydrate metabolism (amino sugar and nucleotide sugar metabolism) were abundant. In addition, nitrogen metabolism and prenyltransferase functions were abundant in the PXSY cohort.

**DISCUSSION**

The gut microbiota is closely associated with the host, and its dysregulation could lead to diseases and inflammation[36-39], such as IBD. Scaldaferri *et al*[40] found that the most severe inflammation was concentrated in the gut of IBD patients at the site with the largest number of microbes, suggesting that changes in the gut microbiota are closely related to intestinal inflammation and that the microbiota affects the host through the immune system[41]. This study is pilot research about the contribution of the gut microbiota to the distinction between the two TCM syndromes of UC and the corresponding molecular mechanism.

According to the TCM theory, PXSY syndrome is a deficiency syndrome, while DCSR syndrome is a sthenia syndrome. Clinical manifestations of the DCSR syndrome focus on the empirical symptoms of intestinal inflammation and injury, while the clinical manifestations of PXSY syndrome focus on the deficiency symptoms of weakened digestion and absorption function. The main clinical symptoms of DCSR syndrome are abdominal pain, diarrhoea, mucous purulent stool, yellowish fur, and thready and slippery pulse. Some of these patients can also show symptoms such as burning pain in the anus, tenesmus, body heat, short red urine, dry or bitter mouth, and ozostomia. The main clinical manifestations in patients with PXSY syndrome include thin sloppy stool, stool mucus that is white rather than red, white frozen, pink tongue, tooth mark around the tongue, and white and greasy tongue coating. Some of these patients may have the symptoms such as dull abdominal pain, abdominal fullness and distention, poor appetite, tiredness, thready and weak pulse, and thready and slippery pulse.

The microbiota in the guts of the healthy cohort and UC patients was investigated in this study, which showed that the richness and diversity of the gut microbiota were different between patients and healthy controls. We found that the intestinal microflora was different between the PXSY and DCSR groups, which is essential for distinguishing the two TCM syndromes of UC and potentially contributes to personalized medicine.

***Microbiota and the pathology of DCSR syndrome***

Using comparisons among PXSY patients, DCSR patients, and healthy subjects, our study illustrated that the genus *Streptococcus* significantly increased in UC patients, especially in patients with DCSR syndrome. The excessive growth of *Streptococcus* in DCSR syndrome patients might indicate the pathological mechanisms of DCSR syndrome.

***Increased Streptococcus in DCSR syndrome***

Dysbiosis of gut microbiota stimulates the inflammatory response of the host and even induces serious complications[42-44]. The RLR signalling pathway is associated with inflammation[45-47]. Here, *Streptococcus*, together with other pathogens in the gut, could stimulate RLRs and produce pro-inflammatory cytokines such as TNF-α *via* the RLR signalling pathway to promote inflammation (Figure 6). However, the continuous stimulation of the RLR signalling pathway results in an excessive inflammatory response. This excessive inflammatory response leaves the intestinal barrier function impaired, and then more microorganisms in the intestinal lumen will pass through an already incomplete epithelial barrier. Finally, these microbiotas will cause inflammation and damage to the intestinal epithelium layer.

***Abundant lactate producers in DCSR syndrome***

The majority of gut microbiota can ferment carbohydrates to produce short-chain fatty acids (SCFAs), lactate, and some inorganic compounds. Some of these products are beneficial to the health of the host, but some harm the intestinal tract, such as by causing damage to the intestinal epithelial barrier or promoting bowel inflammation.

Lactate can be produced by some microbes such as *Streptococcus* in the intestine. The lactate producers can ferment carbohydrates to produce lactic acid, and the accumulation of lactic acid can reduce the pH of the intestinal tract. It has been reported that the over-accumulation of lactate in the intestine of patients leads to a decrease in the pH[48-49]. In disease status, disorder of the gut microbiota appears, and blooms of lactate producers are significant in DCSR syndrome. *Streptococcus* in the presence of other lactate producers (*Enterococcus*, *Lactobacillus*, *Bifidobacterium* and so on)[50-54] can produce lactate. Nevertheless, the utilization rate of lactate by other microbes is decreased in disease status, which causes the over-accumulation of lactic acid in the gut so that the intestinal pH is reduced and the distribution and abundance of intestinal microbiota are changed. Additionally, the accumulation of lactate can stimulate the intestinal tract and aggravate inflammation.

***Lachnoclostridium is raised in PXSY patients***

This study showed that the abundance of *Lachnoclostridium* in the PXSY group was higher than that in the DCSR group. Members of *Lachnoclostridium* ferment some monosaccharides and disaccharides to acetate as the major SCFA products[55]. Within the genus *Lachnoclostridium*, the differential microbes between DCSR and PXSY patients, the main differential species is *Clostridium citroniae*, which also increased in DCSR patients. *Clostridium citroniae* contains D-cysteine desulfatase[56] and can ferment cysteine to sulfide, pyruvate, and ammonia as end products[57], and more *Clostridium citroniae* in the PXSY group suggested that more D-cysteine desulfatase might be present in the intestine of spleen-deficient PXSY patients than in DCSR patients.

The carbohydrate fermentation conducted by bacteria in the colon gives rise to the luminal SCFAs, including acetate, propionate, and butyrate. Among these SCFAs, butyrate is considered to be the preferred source of nutrition and energy for colonic epithelial cells and is, to a major extent, metabolized by these cells[58]. In addition, butyrate is considered to have anti-inflammatory capacity, and the increase in sulfide may inhibit the oxidation of butyrate, which could damage the epithelial barrier and even result in more severe inflammation.

The gut microbiota could also activate a variety of pathogen-associated molecular patterns on the surface of intestinal epithelial cells and downstream signalling pathways, inducing epithelial cells to secrete anti-inflammatory substances[59,60].However, the molecular and metabolic functions of most bacteria are still unknown[60].

*Clostridium citroniae* contains D-cysteine desulfhydrase, which can ferment cysteine to produce sulfides. Here, *Clostridium citroniae* was more abundant in PXSY patients than in DCSR patients and healthy subjects. While in patients with PXSY status, increased *Clostridium citroniae* results in increased D-cysteine desulfhydrase, which results in an increase in sulfides. Finally, sulfides inhibit the oxidization of butyric acid so that the epithelial cells cannot utilize the butyrate in the gut and cause epithelial cell apoptosis. Damage to colonic epithelial cells is reflected in the incomplete intestinal barrier, and gut microbes pass through the intestinal barrier to induce severe inflammation and ulceration. In brief, *Clostridium citroniae* might be detrimental to the health of the intestinal tract by inhibiting the utilization of butyrate.

PXSY syndrome reflects a kind of deficiency in immune activity, while DCSR syndrome is a kind of dysfunction in gut immunity. These differential trends in the microbiota between the two TCM syndromes of UC indicated that different effects were exerted on the mucosal immune activity and the epithelial barrier function by themselves. The genus *Streptococcus*, which could lead to inflammation, was significantly more abundant in DCSR patients. It is suggested that *Streptococcus* and other microbes in the gut might have a certain relationship with DCSR syndrome symptoms such as diarrhoea mixed with blood. These differential microbes are expected to be the markers and therapeutic targets for the clinical precision detection of UC.

There were several weaknesses in the study, like small sample size, non-blinding, and cross-sectional nature. In the following studies, the sample size needs to be further expanded to further strengthen and enrich the accuracy and stability of the research results. This study is a cross-sectional study, and it is difficult to determine the causal relationship between the results. In future studies, the intervention factors can be considered and the dynamic observation before and after the intervention can be carried out.

In conclusion, the gut microbiota is different between patients with PXSY syndrome and those with DCSR syndrome. The genus *Streptococcus* is significantly more abundant in DCSR patients than in PXSY patients, while *Lachnoclostridium* increases in PXSY patients. Dysbiosis of the gut microbiota influences the immune responses of the host, which results in inflammation, and the microbial analysis of the two TCM syndromes essentially reflects different immune activities in the human body, but they all point to promotion of inflammation in the gut.

**ARTICLE HIGHLIGHTS**

***Research background***

Ulcerative colitis (UC) is considered to be closely associated with alteration of intestinal microorganisms. According to the traditional Chinese medicine (TCM) theory, UC can be divided into Pi-Xu-Shi-Yun syndrome (syndrome of spleen deficiency and dampness, PXSY) and Da-Chang-Shi-Re syndrome (syndrome of dampness-heat in the large intestine, DCSR). PXSY syndrome is a deficiency syndrome, while the DCSR syndrome is a sthenia syndrome. However, the relationships among gut microbiota, TCM syndromes, and UC pathogenesis are unclear.

***Research motivation***

The majority of studies have focused on the relationship between intestinal microbiota and the onset of UC, and the contribution of gut microbiota in these two distinct TCM syndromes is still unclarified. This study aimed to compare the difference in microbial composition and function between PXSY and DCSR syndromes to determine the molecular mechanism of TCM in UC by investigation of the gut microbiota.

***Research objectives***

The objective of this study was to investigate the role of gut microbiota in UC and the distinction of microbiota dysbiosis between PXSY and DCSR syndromes.

***Research methods***

We analysed gut microbiome composition of stool samples by 16S rRNA pyrosequencing. We assessed the beta diversity by UniFrac analysis. We also processed the high-throughput sequencing reads with QIIME, and further predicted biological functions using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States.

***Research results***

We determined the composition of gut bacterial communities in 93 stool samples (30 healthy controls, 32 patients with PXSY syndrome, and 31 patients with DCSR syndrome) by 16S rRNA pyrosequencing. Beta diversity showed that the composition of the microbiota was different among the three groups. We found that Porphyromonadaceae, Rikeneliaceae, and Lachnospiraceae significantly decreased while Enterococcus, Streptococcus, and other potential pathogens significantly increased in UC patients compared to healthy subjects at the family level. We further found that *Parabacteroides*, *Dorea*, and *Ruminococcus* decreased while *Faecalibacterium* showed increased abundance in UC compared to healthy controls at the genus level. Five differential taxa were identified between PXSY and DCSR syndromes. We observed a significantly increased abundance of *Streptococcus* in DCSR patients at the genus level, while *Lachnoclostridium* increased in PXSY patients. Additionally, we found that the differential functional pathways of the gut microbiome between the PXSY and DCSR groups mainly included lipid metabolism, immunity, and the metabolism of polypeptides.

***Research conclusions***

The present study identified that the gut microbiota is different between patients with PXSY syndrome and those with DCSR syndrome. The genus *Streptococcus* is significantly more abundant in DCSR patients than in PXSY patients, while *Lachnoclostridium* increases in PXSY patients. The microbial analysis of the two TCM syndromes essentially reflects different immune activities in the human body, but they all point to promotion of inflammation in the gut.

***Research perspectives***

The relationship between TCM syndromes and intestinal flora is an interesting and important research topic. Our study preliminarily explored the characteristics and differences of intestinal flora of patients with two different TCM syndrome. Further studies are required to confirm our findings and to clarify the precise mechanism of intestinal flora characteristics related to TCM deficiency and positive syndrome.

REFERENCES

1 **Molodecky NA**, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012; **142**: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]

2 **Ng SC**. Epidemiology of inflammatory bowel disease: Focus on Asia. *Best Pract Res Clin Gastroenterol* 2014; **28**: 363-372 [PMID: 24913377 DOI: 10.1016/j.bpg.2014.04.003]

3 **Manichanh C**, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. *Nat Rev Gastroenterol Hepatol* 2012; **9**: 599-608 [PMID: 22907164 DOI: 10.1038/nrgastro.2012.152]

4 **Ng SC**, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. *Lancet* 2018; **390**: 2769-2778 [PMID: 29050646 DOI: 10.1016/S0140-6736(17)32448-0]

5 **Kaplan GG**. The global burden of IBD: From 2015 to 2025. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 720-727 [PMID: 26323879 DOI: 10.1038/nrgastro.2015.150]

6 **Ng SC**, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, Wong TC, Leung VK, Tsang SW, Yu HH, Li MF, Ng KK, Kamm MA, Studd C, Bell S, Leong R, de Silva HJ, Kasturiratne A, Mufeena MNF, Ling KL, Ooi CJ, Tan PS, Ong D, Goh KL, Hilmi I, Pisespongsa P, Manatsathit S, Rerknimitr R, Aniwan S, Wang YF, Ouyang Q, Zeng Z, Zhu Z, Chen MH, Hu PJ, Wu K, Wang X, Simadibrata M, Abdullah M, Wu JC, Sung JJY, Chan FKL; Asia–Pacific Crohn's and Colitis Epidemiologic Study (ACCESS) Study Group. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. *Gastroenterology* 2013; **145**: 158-165.e2 [PMID: 23583432 DOI: 10.1053/j.gastro.2013.04.007]

7 **Eaden JA**, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. *Gut* 2001; **48**: 526-535 [PMID: 11247898 DOI: 10.1136/gut.48.4.526]

8 **Desai D**, Shah S, Deshmukh A, Abraham P, Joshi A, Gupta T, Deshpande R, Khandagale V, George S. Colorectal cancers in ulcerative colitis from a low-prevalence area for colon cancer. *World J Gastroenterol* 2015; **21**: 3644-3649 [PMID: 25834332 DOI: 10.3748/wjg.v21.i12.3644]

9 **Lu YH**, Cong LL. [Study on the Chinese medical syndrome distribution of ulcerative colitis]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2012; **32**: 450-454 [PMID: 22803420]

10 **Chen Z**, Wang P. Clinical Distribution and Molecular Basis of Traditional Chinese Medicine ZHENG in Cancer. *Evid Based Complement Alternat Med* 2012; **2012**: 783923 [PMID: 22829858 DOI: 10.1155/2012/783923]

11 **Dai YC**, Zhang YL, Wang LJ, Guo Q, Yang K, Ye RH, Tang ZP. Clinical presentation and treatment strategies for ulcerative colitis: A retrospective study of 247 inpatients. *Chin J Integr Med* 2016; **22**: 811-816 [PMID: 26501692 DOI: 10.1007/s11655-015-2118-1]

12 **Dai YC**, Zheng L, Zhang YL, Chen X, Chen DL, Tang ZP. Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial. *Medicine (Baltimore)* 2017; **96**: e6651 [PMID: 28422869 DOI: 10.1097/MD.0000000000006651]

13 **Zheng L**, Zhang YL, Dai YC, Chen X, Chen DL, Dai YT, Tang ZP. Jianpi Qingchang decoction alleviates ulcerative colitis by inhibiting nuclear factor-κB activation. *World J Gastroenterol* 2017; **23**: 1180-1188 [PMID: 28275298 DOI: 10.3748/wjg.v23.i7.1180]

14 **Lin X**, Yi Z, Diao J, Shao M, Zhao L, Cai H, Fan Q, Yao X, Sun X. ShaoYao decoction ameliorates colitis-associated colorectal cancer by downregulating proinflammatory cytokines and promoting epithelial-mesenchymal transition. *J Transl Med* 2014; **12**: 105 [PMID: 24766737 DOI: 10.1186/1479-5876-12-105]

15 **Liu DY**, Guan YM, Zhao HM, Yan DM, Tong WT, Wan PT, Zhu WF, Liu HN, Liang XL. The protective and healing effects of Si Shen Wan in trinitrobenzene sulphonic acid-induced colitis. *J Ethnopharmacol* 2012; **143**: 435-440 [PMID: 22751005 DOI: 10.1016/j.jep.2012.05.060]

16 **Zou Y**, Lin J, Li W, Wu Z, He Z, Huang G, Wang J, Ye C, Cheng X, Ding C, Zheng X, Chi H. Huangqin-tang ameliorates dextran sodium sulphate-induced colitis by regulating intestinal epithelial cell homeostasis, inflammation and immune response. *Sci Rep* 2016; **6**: 39299 [PMID: 27982094 DOI: 10.1038/srep39299]

17 **Lepage P**, Häsler R, Spehlmann ME, Rehman A, Zvirbliene A, Begun A, Ott S, Kupcinskas L, Doré J, Raedler A, Schreiber S. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. *Gastroenterology* 2011; **141**: 227-236 [PMID: 21621540 DOI: 10.1053/j.gastro.2011.04.011]

18 **Becker C**, Neurath MF, Wirtz S. The Intestinal Microbiota in Inflammatory Bowel Disease. *ILAR J* 2015; **56**: 192-204 [PMID: 26323629 DOI: 10.1093/ilar/ilv030]

19 **Round JL**, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol* 2009; **9**: 313-323 [PMID: 19343057 DOI: 10.1038/nri2515]

20 **Wlodarska M**, Kostic AD, Xavier RJ. An integrative view of microbiome-host interactions in inflammatory bowel diseases. *Cell Host Microbe* 2015; **17**: 577-591 [PMID: 25974300 DOI: 10.1016/j.chom.2015.04.008]

21 **Stephani J**, Radulovic K, Niess JH. Gut microbiota, probiotics and inflammatory bowel disease. *Arch Immunol Ther Exp (Warsz)* 2011; **59**: 161-177 [PMID: 21445715 DOI: 10.1007/s00005-011-0122-5]

22 **Cucchiara S**, Stronati L, Aloi M. Interactions between intestinal microbiota and innate immune system in pediatric inflammatory bowel disease. *J Clin Gastroenterol* 2012; **46 Suppl**: S64-S66 [PMID: 22955361 DOI: 10.1097/MCG.0b013e31826a857f]

23 **Guo M**, Ding S, Zhao C, Gu X, He X, Huang K, Luo Y, Liang Z, Tian H, Xu W. Red Ginseng and Semen Coicis can improve the structure of gut microbiota and relieve the symptoms of ulcerative colitis. *J Ethnopharmacol* 2015; **162**: 7-13 [PMID: 25554637 DOI: 10.1016/j.jep.2014.12.029]

24 **Nishikawa J**, Kudo T, Sakata S, Benno Y, Sugiyama T. Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis. *Scand J Gastroenterol* 2009; **44**: 180-186 [PMID: 18825588 DOI: 10.1080/00365520802433231]

25 **Branch of Gastrointestinal Diseases.**;China Association of Chinese Medicine.[Consensus on Chinese medical diagnosis and treatment of ulcerative colitis (2009)].*Zhongguo Zhong Xi Yi Jie He Za Zhi*2010; **30**: 527-532 [PMID: 20681286]

26 **Bolger AM**, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics* 2014; **30**: 2114-2120 [PMID: 24695404 DOI: 10.1093/bioinformatics/btu170]

27 **Caporaso JG**, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* 2010; **7**: 335-336 [PMID: 20383131 DOI: 10.1038/nmeth.f.303]

28 **Edgar RC**, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. *Bioinformatics* 2011; **27**: 2194-2200 [PMID: 21700674 DOI: 10.1093/bioinformatics/btr381]

29 **Langille MG**, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Vega Thurber RL, Knight R, Beiko RG, Huttenhower C. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nat Biotechnol* 2013; **31**: 814-821 [PMID: 23975157 DOI: 10.1038/nbt.2676]

30 **Segata N**, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. *Genome Biol* 2011; **12**: R60 [PMID: 21702898 DOI: 10.1186/gb-2011-12-6-r60]

31 **Afgan E**, Baker D, van den Beek M, Blankenberg D, Bouvier D, Čech M, Chilton J, Clements D, Coraor N, Eberhard C, Grüning B, Guerler A, Hillman-Jackson J, Von Kuster G, Rasche E, Soranzo N, Turaga N, Taylor J, Nekrutenko A, Goecks J. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. *Nucleic Acids Res* 2016; **44**: W3-W10 [PMID: 27137889 DOI: 10.1093/nar/gkw343]

32 **Lavelle A**, Lennon G, O'Sullivan O, Docherty N, Balfe A, Maguire A, Mulcahy HE, Doherty G, O'Donoghue D, Hyland J, Ross RP, Coffey JC, Sheahan K, Cotter PD, Shanahan F, Winter DC, O'Connell PR. Spatial variation of the colonic microbiota in patients with ulcerative colitis and control volunteers. *Gut* 2015; **64**: 1553-1561 [PMID: 25596182 DOI: 10.1136/gutjnl-2014-307873]

33 **Mar JS**, LaMere BJ, Lin DL, Levan S, Nazareth M, Mahadevan U, Lynch SV. Disease Severity and Immune Activity Relate to Distinct Interkingdom Gut Microbiome States in Ethnically Distinct Ulcerative Colitis Patients. *MBio* 2016; **7**: pii: e01072-16 [PMID: 27531910 DOI: 10.1128/mBio.01072-16]

34 **Frank DN**, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A* 2007; **104**: 13780-13785 [PMID: 17699621 DOI: 10.1073/pnas.0706625104]

35 **Ohkusa T**, Koido S. Intestinal microbiota and ulcerative colitis. *J Infect Chemother* 2015; **21**: 761-768 [PMID: 26346678 DOI: 10.1016/j.jiac.2015.07.010]

36 **Jiao N**, Baker SS, Nugent CA, Tsompana M, Cai L, Wang Y, Buck MJ, Genco RJ, Baker RD, Zhu R, Zhu L. Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents: A meta-analysis. *Physiol Genomics* 2018; **50**: 244-254 [PMID: 29373083 DOI: 10.1152/physiolgenomics.00114.2017]

37 **Jiao N**, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, Tsompana M, Mastrandrea L, Buck MJ, Baker RD, Genco RJ, Zhu R, Zhu L. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. *Gut* 2018; **67**: 1881-1891 [PMID: 28774887 DOI: 10.1136/gutjnl-2017-314307]

38 **Zhu L**, Liu W, Alkhouri R, Baker RD, Bard JE, Quigley EM, Baker SS. Structural changes in the gut microbiome of constipated patients. *Physiol Genomics* 2014; **46**: 679-686 [PMID: 25073603 DOI: 10.1152/physiolgenomics.00082.2014]

39 **Zhu L**, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. *Hepatology* 2013; **57**: 601-609 [PMID: 23055155 DOI: 10.1002/hep.26093]

40 **Scaldaferri F**, Gerardi V, Lopetuso LR, Del Zompo F, Mangiola F, Boškoski I, Bruno G, Petito V, Laterza L, Cammarota G, Gaetani E, Sgambato A, Gasbarrini A. Gut microbial flora, prebiotics, and probiotics in IBD: Their current usage and utility. *Biomed Res Int* 2013; **2013**: 435268 [PMID: 23991417 DOI: 10.1155/2013/435268]

41 **Hooper LV**, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science* 2012; **336**: 1268-1273 [PMID: 22674334 DOI: 10.1126/science.1223490]

42 **Tahara T**, Arisawa T. Pathogenesis of CpG island methylator phenotype-positive colorectal cancers: Role of genetic alteration and colonic flora. *Epigenomics* 2014; **6**: 249-251 [PMID: 25111477 DOI: 10.2217/epi.14.25]

43 **Cui DJ**, Yang XL, Hu M, Yang LC. Effects of Preoperative Methotrexate on Complications After Surgery for Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2017; **23**: E2 [PMID: 27893545 DOI: 10.1097/MIB.0000000000000971]

44 **Van Der Sloot KW**, Joshi AD, Bellavance DR, Gilpin KK, Stewart KO, Lochhead P, Garber JJ, Giallourakis C, Yajnik V, Ananthakrishnan AN, Alizadeh BZ, Xavier RJ, Khalili H. Visceral Adiposity, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease. *Inflamm Bowel Dis* 2017; **23**: 82-88 [PMID: 27893544 DOI: 10.1097/MIB.0000000000000978]

45 **Chu H**, Mazmanian SK. Innate immune recognition of the microbiota promotes host-microbial symbiosis. *Nat Immunol* 2013; **14**: 668-675 [PMID: 23778794 DOI: 10.1038/ni.2635]

46 **Errett JS**, Gale M. Emerging complexity and new roles for the RIG-I-like receptors in innate antiviral immunity. *Virol Sin* 2015; **30**: 163-173 [PMID: 25997992 DOI: 10.1007/s12250-015-3604-5]

47 **Nakhaei P**, Genin P, Civas A, Hiscott J. RIG-I-like receptors: Sensing and responding to RNA virus infection. *Semin Immunol* 2009; **21**: 215-222 [PMID: 19539500 DOI: 10.1016/j.smim.2009.05.001]

48 **Vernia P**, Caprilli R, Latella G, Barbetti F, Magliocca FM, Cittadini M. Fecal lactate and ulcerative colitis. *Gastroenterology* 1988; **95**: 1564-1568 [PMID: 3181680 DOI: 10.1016/S0016-5085(88)80078-7]

49 **Hirschhaeuser F**, Sattler UG, Mueller-Klieser W. Lactate: A metabolic key player in cancer. *Cancer Res* 2011; **71**: 6921-6925 [PMID: 22084445 DOI: 10.1158/0008-5472.CAN-11-1457]

50 **Le Blay G**, Michel C, Blottière HM, Cherbut C. Prolonged intake of fructo-oligosaccharides induces a short-term elevation of lactic acid-producing bacteria and a persistent increase in cecal butyrate in rats. *J Nutr* 1999; **129**: 2231-2235 [PMID: 10573555 DOI: 10.1093/jn/129.12.2231]

51 **Belenguer A**, Duncan SH, Holtrop G, Anderson SE, Lobley GE, Flint HJ. Impact of pH on lactate formation and utilization by human fecal microbial communities. *Appl Environ Microbiol* 2007; **73**: 6526-6533 [PMID: 17766450 DOI: 10.1128/AEM.00508-07]

52 **de Matos BM**, Brighenti FL, Do T, Beighton D, Koga-Ito CY. Acidogenicity of dual-species biofilms of bifidobacteria and Streptococcus mutans. *Clin Oral Investig* 2017; **21**: 1769-1776 [PMID: 27660160 DOI: 10.1007/s00784-016-1958-1]

53 **Belenguer A**, Holtrop G, Duncan SH, Anderson SE, Calder AG, Flint HJ, Lobley GE. Rates of production and utilization of lactate by microbial communities from the human colon. *FEMS Microbiol Ecol* 2011; **77**: 107-119 [PMID: 21395623 DOI: 10.1111/j.1574-6941.2011.01086.x]

54 **Yutin N**, Galperin MY. A genomic update on clostridial phylogeny: Gram-negative spore formers and other misplaced clostridia. *Environ Microbiol* 2013; **15**: 2631-2641 [PMID: 23834245 DOI: 10.1111/1462-2920.12173]

55 **Feng Y**, Stams AJM, de Vos WM, Sánchez-Andrea I. Enrichment of sulfidogenic bacteria from the human intestinal tract. *FEMS Microbiol Lett* 2017; **364** [PMID: 28158432 DOI: 10.1093/femsle/fnx028]

56 **Nagasawa T**, Ishii T, Kumagai H, Yamada H. D-Cysteine desulfhydrase of Escherichia coli. Purification and characterization. *Eur J Biochem* 1985; **153**: 541-551 [PMID: 3908101 DOI: 10.1111/j.1432-1033.1985.tb09335.x]

57 **Tedelind S**, Westberg F, Kjerrulf M, Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: A study with relevance to inflammatory bowel disease. *World J Gastroenterol* 2007; **13**: 2826-2832 [PMID: 17569118 DOI: 10.1186/1471-230X-7-17]

58 **Cawich SO**, Harnarayan P, Budhooram S, Naraynsingh V. Axillary Artery Injury Accompanying Humeral Neck Fracture. *Int J Angiol* 2015; **24**: 296-299 [PMID: 26648673 DOI: 10.1055/s-0034-1372246]

59 **Gupta AK**, Harris JD, Erickson BJ, Abrams GD, Bruce B, McCormick F, Nicholson GP, Romeo AA. Surgical management of complex proximal humerus fractures-a systematic review of 92 studies including 4500 patients. *J Orthop Trauma* 2015; **29**: 54-59 [PMID: 25162974 DOI: 10.1097/BOT.0000000000000229]

60 **Qin J**, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010; **464**: 59-65 [PMID: 20203603 DOI: 10.1038/nature08821]

**P-Reviewer:** Day AS, Madnani MA, Serban ED, Tsujikawa T, Vasudevan A **S-Editor:** Yan JP

**L-Editor:** Wang TQ **E-Editor:**

**Specialty type:** Gastroenterology and hepatology
**Country of origin:** China
**Peer-review report classification**
**Grade A (Excellent):** 0
**Grade B (Very good):**0
**Grade C (Good):** C, C, C, C
**Grade D (Fair):** D **Grade E (Poor):** 0

**Table 1 Characteristics of patients and healthy subjects**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HC** | **DCSR** | **PXSY** |
| Gender |  |  |  |
| Male | 15 | 15 | 17 |
| Female | 15 | 16 | 15 |
| Age (mean ± SD), yr | 43.13 ± 10.98 | 44.16 ± 11.49 | 41.94 ± 13.42 |
| Duration of disease |  |  |  |
| <1 yr |  | 4 | 4 |
| 1-3 yr |  | 11 | 13 |
| 3-5 yr |  | 12 | 11 |
| >5 yr |  | 4 | 4 |
| Inflammation location |
|  Rectum |  | 5 | 5 |
|  Left colon |  | 21 | 22 |
|  Whole colon |  | 5 | 5 |
| Disease activity |  |  |  |
|  Clinical remission |  | 7 | 9 |
|  Mild activity |  | 9 | 9 |
|  Moderate activity |  | 7 | 7 |
|  Severe activity |  | 8 | 7 |

HC: Healthy controls; DCSR: Da-Chang-Shi-Re syndrome; PXSY: Pi-Xu-Shi-Yun syndrome. There were no significant differences among the three groups in gender, age, duration of disease, inflammation location, or disease activity (*P* > 0.05).

**Table 2 Abundant taxa in healthy subjects and patients**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **HC** | **UC** | **PXSY** | **DCSR** | **UC-H FDR** | **P-H *P*1** | **D-H *P*1** | **D-P *P***1 |
| *Bacteroidetes* | 47.02 | 41.3 | 49.09 | 33.26 | 0.25 | 1.00 | **0.03** | **0.01** |
| *Paraprevotellaceae* | 1.04 | 0.18 | 0.35 | 0.00 | **0.02** | 0.07 | **0.02** | 1.00 |
| *Porphyromonadaceae* | 4.8 | 1.86 | 2.55 | 1.15 | **0.01** | **0.04** | **0.01** | 1.00 |
| *Parabacteroides* | 4.79 | 1.83 | 2.55 | 1.09 | **0.01** | **0.05** | **0.00** | 1.00 |
| *Rikenellaceae* | 1.66 | 0.71 | 1.15 | 0.25 | **0.04** | 0.11 | **0.04** | 1.00 |
| *Alistipes* | 1.53 | 0.59 | 0.94 | 0.24 | **0.03** | 0.06 | **0.03** | 1.00 |
| *Firmicutes* | 43.74 | 48.23 | 41.1 | 55.59 | 0.38 | 1.00 | 0.06 | **0.01** |
| *Enterococcaceae* | 0.03 | 0.68 | 0.31 | 1.05 | **0.01** | **0.02** | **0.03** | 1.00 |
| *Enterococcus* | 0.03 | 0.68 | 0.31 | 1.05 | **0.02** | **0.02** | **0.03** | 1.00 |
| *Streptococcaceae* | 0.7 | 2.57 | 1.25 | 3.95 | **0.01** | 0.79 | **0.00** | **0.01** |
| *Streptococcus* | 0.67 | 2.54 | 1.23 | 3.89 | **0.01** | 0.58 | **0.00** | **0.01** |
| *Lachnospiraceae* | 24.18 | 15.78 | 13.91 | 17.71 | **0.01** | **0.01** | **0.03** | 1.00 |
| *Uncultured* | 2.99 | 0.94 | 0.5 | 1.39 | **0.00** | **0.00** | **0.02** | 0.38 |
| *Dorea* | 8.87 | 2.83 | 2.51 | 3.17 | **0.01** | **0.00** | **0.02** | 1.00 |
| *Lachnoclostridium\** | 1.16 | 1.04 | 1.65 | 0.41 | 0.2 | **0.01** | 1.00 | **0.01** |
| *Unknown* | 2.28 | 1.23 | 1.2 | 1.26 | **0.01** | **0.02** | **0.02** | 1.00 |
| *Ruminococcaceae* | 8.46 | 14.56 | 10.72 | 18.52 | 0.08 | 1.00 | **0.01** | 0.17 |
| *Faecalibacterium* | 4.24 | 10.75 | 6.48 | 15.15 | **0.00** | 0.11 | **0.00** | 0.09 |
| *Oscillospira* | 0.61 | 1.4 | 1.65 | 1.13 | 0.08 | **0.01** | 1.00 | 0.17 |
| *Ruminococcus* | 1.63 | 0.42 | 0.45 | 0.39 | **0.00** | **0.01** | **0.00** | 0.84 |
| *Veillonellaceae* | 6.4 | 8.44 | 10.24 | 6.58 | 0.37 | 0.6 | 1.00 | 1.00 |
| *Dialister* | 0.81 | 3.43 | 5.3 | 1.51 | 0.2 | **0.03** | 1.00 | 0.05 |
| *Phascolarctobacterium* | 1.13 | 0.68 | 0.5 | 0.86 | **0.04** | **0.01** | 0.26 | 0.61 |
| *Proteobacteria* | 7.1 | 8.6 | 7.61 | 9.63 | 0.63 | 1.00 | 1.00 | 1.00 |
| *Alcaligenaceae* | 1.77 | 1.29 | 0.95 | 1.64 | **0.04** | **0.02** | 0.19 | 1.00 |
| *Sutterella* | 1.77 | 1.29 | 0.95 | 1.64 | **0.05** | **0.02** | 0.19 | 1.00 |
| *Enterobacteriaceae* | 4.47 | 5.97 | 5.61 | 6.34 | 0.76 | 1.00 | 1.00 | 1.00 |
| Unknown | 0.14 | 0.62 | 0.22 | 1.03 | 0.06 | 0.38 | **0.02** | 0.65 |

The average abundance in gut microbiota in each study group is listed as a percentage. Differential taxa with an average abundance greater than 1% in any of the groups are listed. The significantly differential genera with *P*-values < 0.05 are highlighted in bold. 1Taxa that were renamed after blasting again in NCBI (The National Center for Biotechnology Information). *P*1: *P*-value adjusted by the Bonferroni correction. HC: Healthy controls; DCSR: Da-Chang-Shi-Re syndrome; PXSY: Pi-Xu-Shi-Yun syndrome; UC: Ulcerative colitis; FDR: False discovery rate.



**Figure 1 Rarefaction curves of all samples.** The rarefaction curve of each sample reached a plateau when approximately 2700 sequences per sample were extracted, and Good’s coverage estimator for each group approached 100% (>98.9%).



**Figure 2 Principal coordinate analysis plot of the community structure in healthy controls, patients with Pi-Xu-Shi-Yun syndrome, and those with Da-Chang-Shi-Re syndrome.** The majority of samples clustered by health status at the PC1 *vs* PC3 plot, indicating that health status was a major effect factor for the phylogenetic composition of these samples. Exceptions from all the three study groups were observed, reflecting the effect of other genetic and environmental factors on these microbiomes. PCOA: Principal coordinate analysis; HC: Healthy controls; DCSR: Da-Chang-Shi-Re syndrome; PXSY: Pi-Xu-Shi-Yun syndrome.



**Figure 3 Differential taxa between Pi-Xu-Shi-Yun syndrome and Da-Chang-Shi-Re syndrome cohorts at the genus and species levels.** A: Differential genera; B: Differential species. *Lachnoclostridium* is more abundant in Pi-Xu-Shi-Yun (PXSY) syndrome. *Lachnoclostridium* is more abundant in PXSY syndrome than in the shire group and healthy controls; the species of *Lachnoclostridium* named *Clostridium citroniae* also showed the same tendency. Streptococcus was more abundant in Da-Chang-Shi-Re patients than in PXSY and healthy controls. Relative abundance values are the mean ± SE (adjusted a*P* < 0.05; adjusted b*P* < 0.01; adjusted c*P* < 0.001). HC: Healthy controls; DCSR: Da-Chang-Shi-Re syndrome; PXSY: Pi-Xu-Shi-Yun syndrome.



**Figure 4** **Lactic acid producers in the gut.** Lactic acid bacteria were more abundant in ulcerative colitis patients, especially in the Da-Chang-Shi-Re (DCSR) group, than in healthy controls, suggesting that there might be more lactic acid in the guts of DCSR patients than in those of Pi-Xu-Shi-Yun patients. HC: Healthy controls; DCSR: Da-Chang-Shi-Re syndrome; PXSY: Pi-Xu-Shi-Yun syndrome.



**Figure 5 Functional pathways of gut microbiomes in the Pi-Xu-Shi-Yun and Da-Chang-Shi-Re groups.** Microbial functions were predicted and categorized into KEGG pathways using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States. Linear discriminant analysis effect size was carried out to detect inner function differentials among groups. Significantly differential functions between Pi-Xu-Shi-Yun syndrome (yellow) and Da-Chang-Shi-Re syndrome (pink) are shown (LDA score > 2.0). DCSR: Da-Chang-Shi-Re syndrome; PXSY: Pi-Xu-Shi-Yun syndrome.



**Figure 6 The probable contribution of the gut microbiota to the pathological mechanism of Da-Chang-Shi-Re and Pi-Xu-Shi-Yun syndromes.** Da-Chang-Shi-Re and Pi-Xu-Shi-Yun syndromes might have different pathological mechanisms, which are based on the differential microbiota between these two syndromes. UC: Ulcerative colitis; DCSR: Da-Chang-Shi-Re syndrome; PXSY: Pi-Xu-Shi-Yun syndrome; RLR: RIG-I-like receptor.